ESC quality indicators for post-myocardial infarction care: transition and chronic coronary syndrome phases.

Eur J Prev CardiolSep 4, 2026
Clinical ResearchCardiologyPreventive Medicine / Public Health

Baris Gencer, Cedric Follonier, Amr Abdelrahman et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review developed quality indicators (QIs) for post-myocardial infarction care, focusing on the transition to chronic coronary syndrome. Collaborating with the European Association of Preventive Cardiology, 18 QIs were identified across seven domains of care. These indicators aim to standardize long-term management and address care gaps for high-risk patients after myocardial infarction.

Key findings

  • Eighteen quality indicators were identified across seven domains of post-MI care.
  • The QIs were developed using a systematic review and a modified Delphi approach.
  • The indicators align with the 2024 ESC guidelines on chronic coronary syndromes.

Why it matters

Standardizing care through quality indicators can enhance the long-term management of patients post-myocardial infarction, potentially improving outcomes and reducing variations in clinical practice.

Source

PubMed · PMID 41342498

Published in Eur J Prev Cardiol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Cardiology

Clinical ResearchOncology (Medical)

Osimertinib With or Without Chemotherapy in Advanced Non-Small Cell Lung Cancer With EGFR and Concurrent TP53 Mutations: A Randomized Clinical Trial.

This phase 3 randomized clinical trial evaluated the efficacy and safety of osimertinib combined with chemotherapy versus osimertinib alone in 294 patients with advanced non-small cell lung cancer (NSCLC) harboring…

JAMASep 8, 2026Open accessRead summary
Clinical ResearchHematology

Azacitidine-Venetoclax or Induction Chemotherapy for Acute Myeloid Leukemia.

This phase 2 randomized trial compared azacitidine plus venetoclax to induction chemotherapy in 172 previously untreated adults with acute myeloid leukemia (AML) eligible for induction.

N Engl J MedSep 3, 2026Read summary
Clinical ResearchPsychiatry

The efficacy of modified psychodynamic psychotherapy for patients with schizophrenia-spectrum disorders in Germany: a prospective, single-centre, assessor-blinded, parallel-group, randomised controlled trial.

This randomized controlled trial evaluated the efficacy of Modified Psychodynamic Psychotherapy for Schizophrenia (MPP-S) combined with treatment as usual (TAU) in 130 outpatients with schizophrenia-spectrum disorders…

Lancet PsychiatrySep 10, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.